↓ Skip to main content

Tegaderm CHG IV Securement Dressing for Central Venous and Arterial Catheter Insertion Sites: A NICE Medical Technology Guidance

Overview of attention for article published in Applied Health Economics and Health Policy, October 2015
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (72nd percentile)
  • Good Attention Score compared to outputs of the same age and source (68th percentile)

Mentioned by

policy
1 policy source
twitter
2 X users
facebook
1 Facebook page

Citations

dimensions_citation
36 Dimensions

Readers on

mendeley
118 Mendeley
Title
Tegaderm CHG IV Securement Dressing for Central Venous and Arterial Catheter Insertion Sites: A NICE Medical Technology Guidance
Published in
Applied Health Economics and Health Policy, October 2015
DOI 10.1007/s40258-015-0202-5
Pubmed ID
Authors

Michelle Jenks, Joyce Craig, William Green, Neil Hewitt, Mick Arber, Andrew Sims

Abstract

Catheters are widely used for vascular access and for the administration of drugs or fluids in critically ill patients. This exposes patients to an infection risk. Tegaderm chlorhexidine gluconate (CHG) (developed by 3M)-a transparent securement dressing-covers and protects catheter sites and secures devices to the skin. It comprises a transparent adhesive dressing to act as a barrier against external contamination and an integrated gel pad containing an antiseptic agent. The Medical Technologies Advisory Committee (MTAC) at the National Institute for Health and Care Excellence (NICE) selected Tegaderm CHG for evaluation. One study was identified by the sponsor as relevant to the decision problem. From this, the sponsor concluded that compared with standard dressings, Tegaderm CHG is associated with lower rates of catheter-related infection, but increased dermatitis incidence. The External Assessment Centre (EAC) identified four paired comparative studies between Tegaderm CHG, other CHG dressings or standard dressings. The EAC agreed with the sponsor's conclusion, finding that CHG dressings reduce infections compared with standard dressings. The sponsor constructed a de novo costing model. Tegaderm CHG generated cost savings of £77.26 per patient compared with standard dressings and was cost saving in 98.5 % of a sample of sets of inputs (2013 prices). The EAC critiqued and updated the model's inputs, yielding similar results to those the sponsor estimate. The MTAC reviewed the evidence and decided to support the case for adoption, issuing a positive draft recommendation. After a public consultation, NICE published this as Medical Technology Guidance 25.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 118 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 <1%
Brazil 1 <1%
Unknown 116 98%

Demographic breakdown

Readers by professional status Count As %
Other 16 14%
Researcher 14 12%
Student > Master 14 12%
Student > Bachelor 13 11%
Student > Ph. D. Student 6 5%
Other 19 16%
Unknown 36 31%
Readers by discipline Count As %
Nursing and Health Professions 34 29%
Medicine and Dentistry 22 19%
Agricultural and Biological Sciences 4 3%
Business, Management and Accounting 3 3%
Materials Science 3 3%
Other 13 11%
Unknown 39 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 January 2017.
All research outputs
#6,154,146
of 22,830,751 outputs
Outputs from Applied Health Economics and Health Policy
#264
of 774 outputs
Outputs of similar age
#75,155
of 279,097 outputs
Outputs of similar age from Applied Health Economics and Health Policy
#5
of 16 outputs
Altmetric has tracked 22,830,751 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 774 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.9. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 279,097 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.